drugset

drugset / Trial / NCT03389126

Phase II Study of Avelumab in Patients With Advanced Hepatocellular Carcinoma After Prior Sorafenib Treatment

NCT03389126 ↗

Phase 2 Completed 30 enrolled Seoul National University Hospital Merck KGaA, Darmstadt, Germany · collab

NaSingle-groupOpen-labelTreatment

Summary

An open label, single arm, Phase II study of avelumab in patients with advanced hepatocellular carcinoma after prior sorafenib treatment

Timeline

Start: 2017-12-01
Primary completion: 2019-12-31
Completion: 2020-01-31

Publications

Lee DW, Cho EJ, Lee JH, Yu SJ, Kim YJ, Yoon JH, Kim TY, Han SW, Oh DY, Im SA, Kim TY, Lee Y, Kim H, Lee KH. Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib. Clin Cancer Res. 2021 Feb 1;27(3):713-718. doi: 10.1158/1078-0432.CCR-20-3094. Epub 2020 Nov 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Avelumab	Monoclonal antibody	10 mg/kg	Intravenous

Indications